These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 9665183)
1. Cellular resistance mechanisms with impact on the therapy of multiple myeloma. Gieseler F; Nüssler V Leukemia; 1998 Jul; 12(7):1009-12. PubMed ID: 9665183 [TBL] [Abstract][Full Text] [Related]
2. Cellular resistance mechanisms with impact on the therapy of multiple myeloma. Gieseler F; Nüssler V Leukemia; 1997 Dec; 11 Suppl 5():S1-4. PubMed ID: 9436930 [TBL] [Abstract][Full Text] [Related]
3. Oncogenes in multiple myeloma: point mutation of N-ras. Paquette RL; Berenson J; Lichtenstein A; McCormick F; Koeffler HP Oncogene; 1990 Nov; 5(11):1659-63. PubMed ID: 2267133 [TBL] [Abstract][Full Text] [Related]
4. Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype. Pope B; Brown R; Luo XF; Gibson J; Joshua D Leuk Lymphoma; 1997 May; 25(5-6):545-54. PubMed ID: 9250826 [TBL] [Abstract][Full Text] [Related]
5. Advances in the biology and treatment of multiple myeloma. Varterasian ML Curr Opin Oncol; 1999 Jan; 11(1):3-8. PubMed ID: 9914870 [TBL] [Abstract][Full Text] [Related]
6. Apoptotic signaling in multiple myeloma: therapeutic implications. Chauhan D; Hideshima T; Anderson KC Int J Hematol; 2003 Aug; 78(2):114-20. PubMed ID: 12953804 [TBL] [Abstract][Full Text] [Related]
7. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Tu Y; Renner S; Xu F; Fleishman A; Taylor J; Weisz J; Vescio R; Rettig M; Berenson J; Krajewski S; Reed JC; Lichtenstein A Cancer Res; 1998 Jan; 58(2):256-62. PubMed ID: 9443402 [TBL] [Abstract][Full Text] [Related]
8. Molecular aspects of multiple myeloma. Kastrinakis NG; Gorgoulis VG; Foukas PG; Dimopoulos MA; Kittas C Ann Oncol; 2000 Oct; 11(10):1217-28. PubMed ID: 11106109 [TBL] [Abstract][Full Text] [Related]
9. The oncoprotein phenotype of plasma cells from patients with multiple myeloma. Brown RD; Pope B; Luo XF; Gibson J; Joshua D Leuk Lymphoma; 1994 Dec; 16(1-2):147-56. PubMed ID: 7696921 [TBL] [Abstract][Full Text] [Related]
10. Targeting Bcl-2 for the treatment of multiple myeloma. Touzeau C; Maciag P; Amiot M; Moreau P Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373 [TBL] [Abstract][Full Text] [Related]
11. Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma. Iyer R; Ding L; Batchu RB; Naugler S; Shammas MA; Munshi NC Leuk Res; 2003 Jan; 27(1):73-8. PubMed ID: 12479855 [TBL] [Abstract][Full Text] [Related]
12. Drug resistance in multiple myeloma: novel therapeutic targets within the malignant clone. Pilarski LM; Mant MJ; Belch AR Leuk Lymphoma; 1999 Jan; 32(3-4):199-210. PubMed ID: 10037018 [TBL] [Abstract][Full Text] [Related]
13. [Role of thalidomide in the treatment of multiple myeloma]. Mikala G; Jákó J; Vályi-Nagy I Orv Hetil; 2001 Aug; 142(33):1789-98. PubMed ID: 11573449 [TBL] [Abstract][Full Text] [Related]
14. The role of P-glycoprotein in drug resistance in multiple myeloma. Abraham J; Salama NN; Azab AK Leuk Lymphoma; 2015 Jan; 56(1):26-33. PubMed ID: 24678978 [TBL] [Abstract][Full Text] [Related]
15. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma. Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725 [TBL] [Abstract][Full Text] [Related]
16. Drug resistance in multiple myeloma: approaches to circumvention. Dalton WS; Jove R Semin Oncol; 1999 Oct; 26(5 Suppl 13):23-7. PubMed ID: 10528891 [TBL] [Abstract][Full Text] [Related]